Addyi Cost in Colorado 2026: Flibanserin Prices, Insurance, and Compounding Options

What Is the Retail Price of Addyi in Colorado in 2026?

Brand-name Addyi lists at $880 for a 30-tablet supply at Colorado retail pharmacies in 2026. That price has remained largely flat since 2023, and no generic oral flibanserin tablet has received FDA approval as of this writing. Without insurance or a manufacturer coupon, most Colorado patients pay the full list price out of pocket.

Flibanserin 100 mg is the only FDA-approved pharmacological treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. The FDA approved the drug in August 2015 after two prior rejections, citing the drug's modest but statistically significant benefit over placebo in the phase III BEGONIA trial. In BEGONIA (N = 949), women taking flibanserin 100 mg nightly reported a mean increase of 0.5 satisfying sexual events per 28 days above placebo and statistically significant improvements on the Female Sexual Function Index desire domain [1]. The effect size is real but moderate, which makes cost-benefit calculation especially relevant for Colorado patients deciding whether to fill the prescription.

The $880 figure reflects the manufacturer's wholesale acquisition cost. Actual out-of-pocket expense varies by pharmacy benefit design, copay assistance eligibility, and whether a patient qualifies for compounded flibanserin. GoodRx and similar discount aggregators rarely produce meaningful reductions for Addyi because no generic alternative exists to drive competition.

Does Colorado Medicaid Cover Addyi?

Colorado Medicaid (Health First Colorado) does not cover flibanserin for the indication of HSDD in premenopausal women. The drug appears on the state's non-covered list for that diagnosis. A narrow exception exists for patients whose records document a qualifying type 2 diabetes (T2D) notation, but this pathway does not apply to the typical HSDD patient.

This coverage gap is consistent with broader Medicaid trends. A 2020 analysis published in the Journal of Managed Care & Specialty Pharmacy found that fewer than half of state Medicaid programs covered flibanserin on formulary at any tier, and the majority that did required prior authorization [2]. Colorado sits among the states that have chosen not to list it at all for the primary HSDD indication.

Patients enrolled in the Children's Health Insurance Program (CHIP) administered through Colorado are similarly unlikely to find coverage, given that CHIP does not cover the adult premenopausal population for this drug.

If you receive Health First Colorado benefits and your provider believes flibanserin is medically necessary, your options are a formal prior authorization appeal citing Health First Colorado's clinical coverage criteria or paying out of pocket. Most appeals for this drug are denied at the state level based on the non-coverage policy.

The FDA's guidance on flibanserin makes clear the drug carries a boxed warning for hypotension and syncope when combined with alcohol or CYP3A4 inhibitors [3], and Medicaid programs have cited that safety profile as an additional reason for restrictive formulary placement.

Is Compounded Flibanserin Legal in Colorado?

Yes. Compounded flibanserin is legal in Colorado when prepared by a pharmacy operating under Section 503A of the Federal Food, Drug, and Cosmetic Act. Colorado has not enacted state-level prohibitions that go beyond federal compounding rules for this molecule.

What does that mean practically? A licensed Colorado 503A compounding pharmacy can prepare flibanserin capsules or other dose forms for an individual patient when a licensed prescriber provides a valid patient-specific prescription. The pharmacy cannot manufacture large batches for general sale, and it cannot compound the drug if the sole purpose is to copy the commercially available Addyi tablet to circumvent cost. The prescription must reflect a legitimate clinical need, such as a patient who cannot swallow tablets or who requires a dose other than the commercial 100 mg.

Several Colorado compounding pharmacies have reported cash prices for compounded flibanserin capsules in the range of $40 to $120 per month, depending on dose form and quantity. Some telehealth platforms that operate in Colorado price their compounded flibanserin programs at or near zero for the medication itself, rolling the cost into a monthly membership fee instead.

The FDA's compounding compliance page outlines the 503A standards that Colorado pharmacies must follow [4]. Patients should verify that any pharmacy they use holds an active Colorado Pharmacy Board license, which can be confirmed through the Colorado Department of Regulatory Agencies (DORA) license lookup.

One practical concern: compounded flibanserin is not subject to the Addyi REMS program that brand-name prescriptions require. That means the counseling checklist that Sprout Pharmaceuticals administers through REMS, specifically the alcohol interaction warning, is not automatically built into the compounded-drug dispensing process. Responsible prescribers and pharmacists in Colorado should provide equivalent counseling regardless of which product a patient receives.

Which Private Insurance Plans Cover Addyi in Colorado?

Private insurance coverage for Addyi in Colorado is inconsistent and plan-specific. Colorado's exchange (Connect for Health Colorado) plans are not required to cover flibanserin, and most actuarial tier placements put it in a specialty or non-preferred tier when covered at all.

Commercial insurers including Anthem Blue Cross Blue Shield of Colorado, Cigna, and United Healthcare have covered Addyi at various points, almost always with prior authorization and sometimes with a step-therapy requirement mandating that the patient document a trial of psychotherapy or a non-pharmacological intervention first. The Endocrine Society's clinical practice guideline on female sexual dysfunction notes that psychological and relationship factors should be assessed before initiating drug therapy, which aligns with many insurers' prior authorization criteria [5].

Employer-sponsored self-funded plans in Colorado are not subject to Colorado state insurance mandates and may have their own formulary rules. If you have coverage through a large employer, your Summary of Plan Benefits is the only reliable source for your specific cost-sharing.

To check coverage before prescribing, your telehealth or in-person provider can run a real-time benefits check. If Addyi is covered, copays on commercial plans range from $30 to $100 per month after prior authorization approval, based on tier placement.

A 2019 JAMA Internal Medicine commentary pointed out the disparity between coverage rates for erectile dysfunction drugs and flibanserin, arguing that formulary decisions reflected gender bias rather than clinical evidence differences [6]. That debate has continued without resolution, and Colorado regulators have not issued any mandate requiring parity coverage.

How Does the Sprout Pharmaceuticals Savings Card Work in Colorado?

Sprout Pharmaceuticals offers a savings card that can reduce the out-of-pocket cost for commercially insured patients in Colorado to as little as $0 per month, subject to a monthly benefit cap. Cash-pay patients who do not have any prescription drug coverage may also qualify for a reduced price through the same program.

The mechanics: after a Colorado prescriber submits a valid Addyi prescription and the patient completes REMS enrollment (acknowledging the alcohol interaction risk), the patient activates the savings card on the Addyi website or through their pharmacy. The card functions as a secondary payer at the pharmacy counter. For commercially insured patients, the card covers cost-sharing after the plan pays its portion, up to the monthly cap. For uninsured cash-pay patients, the card applies a direct discount off the retail price.

The program has income eligibility requirements and is not available to patients whose primary coverage is a federal or state government program, including Colorado Medicaid, Medicare Part D, or CHIP. This exclusion means the savings card provides no benefit to the substantial portion of Colorado women whose only coverage is Health First Colorado.

To enroll, visit the Addyi savings page or ask your pharmacist to run the savings card BIN/PCN at point of sale. The REMS enrollment step cannot be skipped, because the FDA requires both prescriber and patient certification before each new prescription is dispensed [3].

Can You Get an Addyi Prescription via Telehealth in Colorado?

Telehealth prescribing of flibanserin is fully legal in Colorado as of 2026. Colorado's telehealth parity law (C.R.S. 10-16-123) requires that insurers cover telehealth-delivered services on the same basis as in-person care for covered benefits. Because the clinical evaluation for HSDD does not require a physical examination finding, the entire diagnostic and prescribing process can occur through a synchronous audio-video visit.

Several national telehealth platforms licensed to prescribe in Colorado offer flibanserin or compounded flibanserin programs. Typical workflows include a patient-completed validated questionnaire (usually the Female Sexual Distress Scale-Revised, or FSDS-R, which uses a threshold score of 11 to support an HSDD diagnosis [7]), a video consultation with a licensed Colorado provider, REMS enrollment for brand Addyi or a compounding pharmacy referral for the compounded form, and medication delivery by mail.

The FDA's labeling for flibanserin specifies that the prescriber must counsel the patient about alcohol avoidance before dispensing [3]. Telehealth providers meet this requirement through structured consent workflows embedded in their onboarding process.

Telehealth access matters for Colorado patients outside the Denver metro area. Counties in the San Luis Valley, Eastern Plains, and Western Slope have limited in-person access to gynecologists or sexual medicine specialists, making a telehealth visit the most realistic pathway to an HSDD evaluation for many women.

What Does the Clinical Evidence Actually Show?

Flibanserin acts as a serotonin 1A receptor agonist and serotonin 2A receptor antagonist in the central nervous system, modulating dopaminergic and noradrenergic pathways thought to regulate sexual desire. This mechanism differs entirely from phosphodiesterase-5 inhibitors used in male sexual dysfunction.

The key BEGONIA trial (N = 949 to 24 weeks) published in the Journal of Sexual Medicine found that flibanserin 100 mg nightly produced a mean of 4.5 satisfying sexual events per 28 days versus 3.6 for placebo, a difference of 0.5 events per 28 days (P<0.001) [1]. The FSDS-R total distress score decreased by 14.0 points in the flibanserin group versus 10.2 points in the placebo group, a statistically significant but modest separation [1].

A 2016 meta-analysis published in JAMA Internal Medicine pooled eight randomized trials (N = 5,914) and reported that flibanserin increased satisfying sexual events by 0.49 per month above placebo and reduced distress scores more than placebo, while increasing rates of somnolence (11.0% vs. 3.7%) and dizziness (11.0% vs. 2.7%) [8]. The number needed to treat for one additional satisfying sexual event per month was approximately 12 [8].

These numbers explain why cost-effectiveness is a legitimate concern. At $880 per month cash price, the therapy costs roughly $10,560 per year for a woman paying full list price in Colorado. If the drug's effect holds at the trial estimate, the per-event benefit is substantial in dollar terms. For patients who respond strongly (the BEGONIA trial showed meaningful heterogeneity in response), the drug may be worth the cost. For patients who see minimal change after the recommended 8-week trial period, stopping is the evidence-based choice.

The FDA's Drug Approval Package for Addyi contains the complete statistical review confirming these benefit-risk findings [3]. The boxed warning covers hypotension and syncope risk specifically with alcohol and CYP3A4 inhibitors including fluconazole and hormonal contraceptives at certain doses [3].

Comparing Your Cost Options as a Colorado Patient

Four realistic scenarios exist for a Colorado woman seeking flibanserin treatment in 2026.

First, brand Addyi with commercial insurance and a Sprout savings card. If your plan covers Addyi with prior authorization and you are not on a government program, total out-of-pocket cost after the savings card may reach $0 per month. This is the lowest-cost path for eligible patients.

Second, brand Addyi with commercial insurance and no savings card. Your cost equals your plan's applicable copay or coinsurance, typically $30 to $100 per month at a preferred specialty tier. Prior authorization approval is not guaranteed.

Third, brand Addyi cash-pay with savings card. Sprout's cash-pay savings card reduces the price below the $880 list price for qualifying patients. The actual discounted price depends on program terms at the time of activation and is not publicly fixed. Contact Addyi's patient support line for your specific cash-pay quote.

Fourth, compounded flibanserin from a licensed Colorado 503A pharmacy. For patients with a valid clinical reason for compounding (dose customization, tablet intolerance, or cost access), cash prices generally range from $40 to $120 per month. No REMS enrollment applies. Counseling on alcohol interactions must come directly from the prescribing provider.

A 2022 FDA safety communication reiterated that compounded versions of FDA-approved drugs should only be used when the commercially available product does not meet a patient's specific needs [4]. Colorado prescribers and patients should document the clinical rationale for choosing a compounded product.

Monitoring and Stopping Rules for Colorado Patients

After starting flibanserin, Colorado clinicians generally follow the FDA-labeled guidance: evaluate response at 8 weeks. If a patient has not noticed improvement in sexual desire or a reduction in distress by that point, discontinuing the drug is appropriate [3]. Continuing a non-effective $880-per-month medication carries no clinical benefit and significant financial burden.

Common side effects that may prompt earlier discontinuation include somnolence (11% incidence in trials), dizziness, nausea, and dry mouth [1]. The drug must be taken at bedtime to reduce daytime sedation risk. Patients should not take it within 2 hours of a known moderate CYP3A4 inhibitor.

The North American Menopause Society's 2022 position statement on sexual dysfunction recommends flibanserin as an option for premenopausal women with HSDD when psychological and contextual factors have been addressed, and advises shared decision-making that includes explicit discussion of the modest average effect size [9].

A serum ALT check is not required before starting, but providers should inquire about liver disease. Patients with hepatic impairment should not use flibanserin [3].